Last reviewed · How we verify
Topotecan (Chemotherapy)
Topotecan is a topoisomerase I inhibitor that works by interfering with the enzyme topoisomerase I, which is involved in DNA replication and repair.
Topotecan is a topoisomerase I inhibitor that works by interfering with the enzyme topoisomerase I, which is involved in DNA replication and repair. Used for Metastatic ovarian cancer, Small cell lung cancer.
At a glance
| Generic name | Topotecan (Chemotherapy) |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | Topoisomerase inhibitor |
| Target | Topoisomerase I |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting topoisomerase I, topotecan prevents cancer cells from replicating and ultimately leads to cell death. This mechanism is particularly effective in rapidly dividing cancer cells. Topotecan's ability to target topoisomerase I also makes it more effective in certain types of cancer, such as ovarian and small cell lung cancer.
Approved indications
- Metastatic ovarian cancer
- Small cell lung cancer
Common side effects
- Myelosuppression
- Nausea and vomiting
- Diarrhea
- Fatigue
- Neutropenia
Key clinical trials
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery (PHASE1)
- Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (PHASE3)
- A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (PHASE3)
- A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) (PHASE3)
- DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy (PHASE1)
- Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (PHASE2)
- Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topotecan (Chemotherapy) CI brief — competitive landscape report
- Topotecan (Chemotherapy) updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI